CBER Director Peter Marks (Susan Walsh/AP Images)

Thou­sands of gene and cell ther­a­pies are in­un­dat­ing FDA re­view­ers as the agency tries to keep up

The FDA’s staff is flood­ed with thou­sands of cell and gene ther­a­py tri­als mak­ing their way through a short-hand­ed reg­u­la­to­ry work­force.

While the FDA has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.